US2023137870A1PendingUtilityA1

Use of mitochondrial extract to treat and/or prevent kidney injury-related disease

72
Assignee: TAIWAN MITOCHONDRION APPLIED TECH CO LTDPriority: Mar 20, 2020Filed: Mar 19, 2021Published: May 4, 2023
Est. expiryMar 20, 2040(~13.6 yrs left)· nominal 20-yr term from priority
Inventors:Han-Chung ChengChih-Kai HsuHui-Ching Tseng
A61K 38/00A61K 35/16A61K 35/19A61K 35/14A61K 35/28C12N 2500/80C12N 5/0646C12N 5/0634C12N 5/0662A61P 19/04C12N 2501/998C12N 2502/115C12N 5/0018A61P 17/14A61P 43/00A61P 13/12A61P 17/18A61P 19/02C12N 5/0605C12N 2500/84A61M 1/3693A61P 17/02A61P 21/00A61M 1/029C12N 5/0667A61K 35/12A61K 38/36G01N 33/6893A61K 9/0053A61K 9/0019
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention discloses a use of a mitochondrial extract to treat and/or prevent a kidney injury-related disease. Specifically, by administering the mitochondrial extract disclosed in the present invention to a patient having a kidney injury-related disease, the kidney injury-related disease can be effectively alleviated and prevented from deterioration.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A use of mitochondria to prepare a composition for preventing and/or treating a kidney injury-related disease. 
     
     
         2 . The use of  claim 1 , wherein the kidney injury-related disease is kidney fibrosis. 
     
     
         3 . The use of  claim 1 , wherein the kidney injury-related disease is kidney inflammation. 
     
     
         4 . The use of  claim 1 , wherein the kidney injury-related disease has a symptom of a mitochondrial injury. 
     
     
         5 . The use of  claim 1 , wherein the kidney injury-related disease is a chronic kidney disease. 
     
     
         6 . The use of  claim 1 , wherein the kidney injury-related disease is a renal tubular injury. 
     
     
         7 . The use of  claim 6 , wherein the symptom of the renal tubular injury is that the injury area is greater than 25%. 
     
     
         8 . The use of  claim 1 , wherein the dose of the mitochondria in the composition is 5 μg or more. 
     
     
         9 . The use of  claim 1 , wherein the dose of the mitochondria in the composition is 40 μg or more.

Join the waitlist — get patent alerts

Track US2023137870A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.